vs
Datadog（DDOG）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Datadog的季度营收约是Royalty Pharma plc的1.5倍（$953.2M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 4.9%，领先29.6%），Datadog同比增速更快（29.2% vs 4.8%），过去两年Datadog的营收复合增速更高（24.9% vs 4.6%）
Datadog是一家美国企业，为云级应用提供可观测性服务，旗下SaaS数据分析平台可实现对服务器、数据库、各类工具及服务的统一监控。公司成立并总部位于纽约，目前在纳斯达克证券交易所公开上市。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DDOG vs RPRX — 直观对比
营收规模更大
DDOG
是对方的1.5倍
$622.0M
营收增速更快
DDOG
高出24.4%
4.8%
净利率更高
RPRX
高出29.6%
4.9%
两年增速更快
DDOG
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $953.2M | $622.0M |
| 净利润 | $46.6M | $214.2M |
| 毛利率 | 80.4% | — |
| 营业利润率 | 1.0% | 62.4% |
| 净利率 | 4.9% | 34.4% |
| 营收同比 | 29.2% | 4.8% |
| 净利润同比 | 2.1% | 2.9% |
| 每股收益（稀释后） | $0.13 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DDOGRPRX
| Q4 25 | $953.2M | $622.0M | ||
| Q3 25 | $885.7M | $609.3M | ||
| Q2 25 | $826.8M | $578.7M | ||
| Q1 25 | $761.6M | $568.2M | ||
| Q4 24 | $737.7M | $593.6M | ||
| Q3 24 | $690.0M | $564.7M | ||
| Q2 24 | $645.3M | $537.3M | ||
| Q1 24 | $611.3M | $568.0M |
净利润DDOGRPRX
| Q4 25 | $46.6M | $214.2M | ||
| Q3 25 | $33.9M | $288.2M | ||
| Q2 25 | $2.6M | $30.2M | ||
| Q1 25 | $24.6M | $238.3M | ||
| Q4 24 | $45.6M | $208.2M | ||
| Q3 24 | $51.7M | $544.0M | ||
| Q2 24 | $43.8M | $102.0M | ||
| Q1 24 | $42.6M | $4.8M |
毛利率DDOGRPRX
| Q4 25 | 80.4% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 79.9% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 80.5% | — | ||
| Q3 24 | 80.0% | — | ||
| Q2 24 | 80.9% | — | ||
| Q1 24 | 82.0% | — |
营业利润率DDOGRPRX
| Q4 25 | 1.0% | 62.4% | ||
| Q3 25 | -0.7% | 70.1% | ||
| Q2 25 | -4.3% | 36.3% | ||
| Q1 25 | -1.6% | 94.0% | ||
| Q4 24 | 1.3% | 60.9% | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 2.0% | 50.2% | ||
| Q1 24 | 2.0% | -13.0% |
净利率DDOGRPRX
| Q4 25 | 4.9% | 34.4% | ||
| Q3 25 | 3.8% | 47.3% | ||
| Q2 25 | 0.3% | 5.2% | ||
| Q1 25 | 3.2% | 41.9% | ||
| Q4 24 | 6.2% | 35.1% | ||
| Q3 24 | 7.5% | 96.3% | ||
| Q2 24 | 6.8% | 19.0% | ||
| Q1 24 | 7.0% | 0.8% |
每股收益（稀释后）DDOGRPRX
| Q4 25 | $0.13 | $0.49 | ||
| Q3 25 | $0.10 | $0.67 | ||
| Q2 25 | $0.01 | $0.07 | ||
| Q1 25 | $0.07 | $0.55 | ||
| Q4 24 | $0.14 | $0.46 | ||
| Q3 24 | $0.14 | $1.21 | ||
| Q2 24 | $0.12 | $0.23 | ||
| Q1 24 | $0.12 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $401.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $3.7B | $9.7B |
| 总资产 | $6.6B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DDOGRPRX
| Q4 25 | $401.3M | $618.7M | ||
| Q3 25 | $540.6M | $938.9M | ||
| Q2 25 | $489.0M | $631.9M | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $929.0M | ||
| Q3 24 | $337.4M | $950.1M | ||
| Q2 24 | $411.0M | $1.8B | ||
| Q1 24 | $282.2M | $843.0M |
总债务DDOGRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益DDOGRPRX
| Q4 25 | $3.7B | $9.7B | ||
| Q3 25 | $3.4B | $9.6B | ||
| Q2 25 | $3.2B | $9.5B | ||
| Q1 25 | $2.9B | $9.8B | ||
| Q4 24 | $2.7B | $10.3B | ||
| Q3 24 | $2.6B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.2B | $9.9B |
总资产DDOGRPRX
| Q4 25 | $6.6B | $19.6B | ||
| Q3 25 | $6.1B | $19.3B | ||
| Q2 25 | $5.8B | $18.3B | ||
| Q1 25 | $6.0B | $17.6B | ||
| Q4 24 | $5.8B | $18.2B | ||
| Q3 24 | $4.6B | $18.0B | ||
| Q2 24 | $4.4B | $17.7B | ||
| Q1 24 | $4.1B | $16.1B |
负债/权益比DDOGRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $327.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $318.2M | — |
| 自由现金流率自由现金流/营收 | 33.4% | — |
| 资本支出强度资本支出/营收 | 0.9% | — |
| 现金转化率经营现金流/净利润 | 7.02× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流DDOGRPRX
| Q4 25 | $327.1M | $827.1M | ||
| Q3 25 | $251.5M | $702.6M | ||
| Q2 25 | $200.1M | $364.0M | ||
| Q1 25 | $271.5M | $596.1M | ||
| Q4 24 | $265.2M | $742.5M | ||
| Q3 24 | $228.7M | $703.6M | ||
| Q2 24 | $164.4M | $658.2M | ||
| Q1 24 | $212.3M | $664.6M |
自由现金流DDOGRPRX
| Q4 25 | $318.2M | — | ||
| Q3 25 | $234.7M | — | ||
| Q2 25 | $184.9M | — | ||
| Q1 25 | $262.8M | — | ||
| Q4 24 | $257.5M | — | ||
| Q3 24 | $220.3M | — | ||
| Q2 24 | $160.0M | — | ||
| Q1 24 | $198.1M | — |
自由现金流率DDOGRPRX
| Q4 25 | 33.4% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 22.4% | — | ||
| Q1 25 | 34.5% | — | ||
| Q4 24 | 34.9% | — | ||
| Q3 24 | 31.9% | — | ||
| Q2 24 | 24.8% | — | ||
| Q1 24 | 32.4% | — |
资本支出强度DDOGRPRX
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 2.3% | — |
现金转化率DDOGRPRX
| Q4 25 | 7.02× | 3.86× | ||
| Q3 25 | 7.42× | 2.44× | ||
| Q2 25 | 75.58× | 12.06× | ||
| Q1 25 | 11.02× | 2.50× | ||
| Q4 24 | 5.82× | 3.57× | ||
| Q3 24 | 4.42× | 1.29× | ||
| Q2 24 | 3.75× | 6.45× | ||
| Q1 24 | 4.98× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DDOG
| North America | $678.7M | 71% |
| International | $274.5M | 29% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
